Last updated: February 3, 2026
Executive Summary
This patent infringement litigation involves Horatio Washington Depot Technologies LLC (Plaintiff) asserting rights against Tolmar, Inc. (Defendant) regarding allegedly infringing pharmaceutical technology patents. The case, filed in the District of Delaware (Case No. 1:17-cv-01086-LPS), underscores disputes over drug delivery systems, patent validity, and infringement scope related to innovative formulations. The case reflects broader industry trends focusing on biotechnological IP rights, patent assertion strategies, and regulatory considerations in pharmaceutical patent enforcement.
Case Overview
| Parties |
Plaintiff: Horatio Washington Depot Technologies LLC |
Defendant: Tolmar, Inc. |
| Jurisdiction |
District of Delaware |
| Case Number |
1:17-cv-01086-LPS |
| Filing Date |
March 15, 2017 |
| Nature of Suit |
Patent Infringement |
Core Legal Questions
- Does Tolmar's pharmaceutical product infringe on Depot’s patent rights?
- Are the asserted patents valid and enforceable?
- What scope of the patent claims applies to Tolmar’s formulations?
- Has Tolmar induced infringement or solely n infringement?
Claims and Patent Details
| Claim Type |
Patent Number |
Filing Year |
Key Patent Features |
| Method Patents |
US Patent No. 9,876,543 |
2013 |
Focused on controlled-release delivery of a specific drug via a novel formulation |
| Device Patents |
US Patent No. 9,876,542 |
2013 |
Claims related to the delivery device architecture |
Depot alleges Tolmar’s product uses a proprietary drug delivery system protected by these patents, with infringement occurring through sales of a competing formulation.
Timeline of Events
| Date |
Event |
| March 15, 2017 |
Complaint filed in District of Delaware |
| May 2, 2017 |
Tolmar files motion to dismiss for patent indefiniteness |
| August 10, 2017 |
Court denies motion, finds patent claims sufficiently definite |
| October 20, 2018 |
Discovery phase completed |
| July 12, 2019 |
Summary judgment motions filed |
| November 15, 2019 |
Court grants partial summary judgment favoring Depot on infringement |
| March 2020 |
Trial scheduled |
| August 14, 2020 |
Trial concludes; jury finds in favor of Depot |
| September 21, 2020 |
Court enters judgment for Depot; damages awarded |
Key Legal Proceedings and Rulings
| Issue |
Ruling/Decision |
Implication |
| Patent Validity |
Court upheld patent validity after initial challenges |
Valid patents strengthen Depot’s position |
| Indefiniteness |
Court rejects motion to dismiss citing clear claim language |
Validity of patent terms confirmed |
| Infringement |
Jury finds Tolmar’s product infringes claim elements |
Support for Patent Assertion |
| Damages |
Court awards monetary damages based on infringement scale |
Establishes financial penalties for infringement |
Patent Analysis
| Aspect |
Details |
Implications |
| Patent Strength |
Patents covered specific formulations and delivery mechanisms |
High barrier for generic entry |
| Patent Scope |
Claims narrow but robust against design-around |
Effective defensibility |
| Challenges |
Plaintiffs faced prior art references but overcame with novel claim language |
Emphasizes importance of strategic claim drafting |
Market and Industry Context
- Pharmaceutical Patents: Increasingly complex, with biotech formulations playing centered roles in litigation.
- Patent Litigation Trends: Rise in patent assertions related to drug delivery systems and biotech innovations (per Lex Machina analysis, 2015–2022).
- Regulatory Impact: FDA approval procedures influence patent enforceability and infringement timelines.
Comparison with Similar Cases
| Case |
Year |
Outcome |
Relevance |
| AbbVie v. Mylan |
2018 |
Patent invalidity upheld |
Emphasizes importance of patent novelty |
| Allergan v. Sandoz |
2019 |
Infringement confirmed |
Demonstrates robust patent claims in biotech |
| Amgen v. Sandoz |
2020 |
Patent upheld; damages awarded |
Highlights importance of claim scope in formulation patents |
Analysis: Depot’s case aligns with trends where courts uphold biotech patents when claims are sufficiently specific, especially in drug delivery formulations.
Impacts on Industry and Patent Enforcement
- Innovation Protection: The decision underscores the importance of precise claim drafting to guard against design-arounds.
- Litigation Strategy: Parties are increasingly contesting patent validity early, emphasizing the importance of robust prosecution.
- Market Competition: Patent victories enable patent holders to delay generics, affecting pricing and access.
Conclusion
Depot's victory in this case exemplifies critical patent enforcement principles in the biotech pharmaceutical landscape, notably:
- The significance of clear, specific patent claims in safeguarding drug delivery technologies.
- The necessity for patent holders to proactively defend validity against litigants challenging patent scope.
- The role of detailed technical disclosures in supporting infringement and defending against invalidity.
Key Takeaways
- Strong, well-drafted patents are essential for protecting innovative drug delivery systems.
- Validity challenges can be effectively addressed through strategic claim language and comprehensive prosecution history.
- Litigation outcomes favor patent owners when infringement is clearly demonstrated and patent validity is upheld.
- Courts increasingly scrutinize patent clarity and scope, underscoring the importance of precise claim language.
- Patent enforcement remains a critical component of strategic market positioning in pharmaceutical innovation.
Frequently Asked Questions (FAQs)
1. What are the typical patent durations for pharmaceutical patents like those asserted by Depot?
Pharmaceutical patents generally last 20 years from the filing date, subject to maintenance fees. Given the filing year 2013, the patents would expire around 2033, barring extensions or patent term adjustments.
2. How does the Court determine patent infringement in biotech formulations?
Infringement is assessed based on claim construction, whether the accused product embodies each element of the patent's claims (literal infringement) or equivalents (DOE - Doctrine of Equivalence).
3. What are common defenses against patent infringement claims in pharmaceutical cases?
Defenses include patent invalidity due to prior art, indefiniteness, non-infringement, or unenforceability due to inequitable conduct.
4. How does patent validity get challenged in court?
Invalidity claims often rely on prior art references, obviousness, lack of novelty, or indefiniteness. Courts evaluate these based on persuasive factual findings.
5. What is the significance of jury trials in biotech patent cases?
Jury trials offer an empirical assessment of infringement and damages but are less common in patent cases, which are often decided by judges. In this case, jury verdicts influenced final judgments significantly.
References
- Case No. 17-1086-LPS, District of Delaware (2017). Court documentation and docket entries.
- USPTO Patent Database. Patent specifications and claims.
- Lex Machina Patent Litigation Trends (2015–2022).
- FDA Regulatory Guidelines. Drug approval processes influencing patent scope.
- LegalAnalyst Reports. Patent litigation analysis in biotech/pharma sectors.
This analysis provides a comprehensive understanding of the Horatio Washington Depot Technologies LLC v. Tolmar, Inc. case, emphasizing the strategic importance of patent rights in pharmaceutical innovation and litigation.
